Minggu, 09 Maret 2008

Inhaled Insulin (Who Cares?)

Eli Lilly & Company announced that it was halting development of its inhaled insulin product because it no longer believes that the product has sufficient market potential. The company recorded a three-month loss of $90–120 million to shut down the failed project. The announcement comes just five months after the first inhaled insulin product, Pfizer’s Exubera, was pulled from the market because of weak sales.

What happened? For decades, scientists and drug marketers dreamed of blockbuster profits from the first inhalable insulin product that would eliminate the need for injections in the treatment of diabetes. It turns out that no one cared. Patients didn’t like the cumbersome device used to administer the powdered insulin, and doctors found that the powders had a slight tendency to impair lung function.

It seemed like such a good idea.

0 komentar:

Posting Komentar

Copyright 2010 Biology Blog Education. All rights reserved.
Themes by Ex Templates Blogger Templates l Home Recordings l Studio Rekaman